Characterization of NDMM patients treated with daratumumab, lenalidomide, bortezomib and dexamethasone who fail to achieve a VGPR or have early progression
Analysis reveals decreased overall survival in NDMM patients after treatment with daratumumab and dexamethasone, suggesting the need for tailored therapies.
Key Points
The study identified decreased overall survival in NDMM patients who failed to achieve a VGPR after treatment.
Of the cohort, 112 patients were noted to have a lower than expected overall survival rate at 65% at four years.
Observational analysis combined data from the Emory Myeloma Database and Athens' clinical database of 462 patients.
The presence of cytogenetic abnormalities indicates a need for specific treatment approaches for patients not achieving VGPR.
Cite This Study
Gavriatopoulou et al. (2025) studied this question.